B.S. in Science - Pennsylvania State University

Ph.D. in Chemistry - American University

Postdoctoral Fellow in Neuropharmacology - National Institute of Mental Health, NIH

Andrews group research is centered on the serotonin neurotransmitter system. Our goal is to understand the role of serotonin in complex behavior and the etiology and treatment of anxiety disorders and depression. Human cell lines expressing native serotonin transporter gene variants, genetically engineered mice, drugs, neurotoxins and environmental factors are used to probe the molecular bases of normal behavior, disease processes and therapeutic mechanisms. Bioanalytical techniques, including microelectrode voltammetry and microdialysis, are developed and utilized to investigate serotonin neurotransmission, particularly in vivo. Quantitative autoradiography, immunocytochemistry, RT-qPCR and ELISA are used to study neuronal architectures and the expression of key proteins such as brain-derived neurotrophic factor, which are regulated by serotonin. Neurotransmitter-functionalized self-assembled materials have recently been designed for the development of novel in vivo nanobiosensors and functionally-directed proteomics.

• A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. M. A. Fox, A. M. Andrews, J. R. Wendland, K. –P. Lesch, A. Holmes and D. L. Murphy, Psychopharmacology, in press.

• Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. B. P. Guiard, D. P. David, T. Deltheil, J. –P. Guilloux, F. Chenu, E. Le Maître, T. Renoir, I. Leroux-Nicollet, P. Sokoloff, V. Arango, Y. Liu, M. Underwook, L. Lanfumey, M. Hamon, A. M. Andrews, R. Hen and A. M. Gardier, International Journal of Neurospychopharmacology, in press.

• Selecting and driving monolayer structures through tailored intermolecular interactions. T. J. Mullen, A. A. Dameron, A. M. Andrews and P. S. Weiss, Aldrichimica Acta, 40:21-31 (2007).

• Reduced BDNF is associated with a loss of serotonergic innervation in the hippocampus of aging mice. B. A. Luellen, L. E. Bianco, L. M. Schneider and A. M. Andrews, Genes, Brain and Behavior, 6:482-490 (2007).

• Microcontact insertion printing. T. J. Mullen, C. Srinivasan, J. N. Hohman, S. D. Gillmor, M. J. Shuster, M. W. Horn, A. M. Andrews and P. S. Weiss, Applied Physics Letters, 90:063114/1-3 (2007).

• Filtration disrupts synaptosomal membranes during radiochemical assay of serotonin uptake: Comparison with chronoamperometry in SERT knockout mice. X. A. Perez, L. E. Bianco and A. M. Andrews, Journal of Neuroscience Methods, 154:245-255 (2006).

• Radical-induced degradation of liposome-encapsulated microtubules as a model of axonal damage due to oxidative stress. A. E. Counterman, T. G. D'Onofrio, A. M. Andrews and P. S. Weiss, Proceedings of the National Academy of Sciences, USA, 103 :5262-5266 (2006).

• Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human a -synuclein in mice. E. L. Unger, D. Eve, X. A. Perez, D. K. Reichenbach, Y. Xu, M. K. Lee and A. M. Andrews , Neurobiology of Disease , 21 :431-443 (2006).

• The neurotoxin 2'-NH 2 -MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF. B. A. Luellen, M. E. Szapacs, C. K. Materese and A. M. Andrews , Neuropharmacology, 50 :297-308 (2006) .

• Chronoamperometry detects differential changes in synaptosomal uptake in serotonin transporter knockout mice. X. A. Perez and A. M. Andrews , Analytical Chemistry 77 :818-826 (2005) .

• Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. D. -K. Kim, T. J. Tolliver, S. J. Huang, B. J. Martin, A. M. Andrews , C. Wichems, A. Holmes, K. -P. Lesch, D. L. Murphy, Neuropharmacology , 49 :798-810 (2005).

• Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. T. A. Mathews, D. E. Fedele, F. M. Coppelli, A. L. Avila, D. L. Murphy and A. M. Andrews , Journal of Neuroscience Methods 140 :169-181 (2004).

• Late onset loss of hippocampal 5-HT and NE is accompanied by an increase in BDNF protein expression in mice co-expressing mutant APP and PS1 . M. E. Szapacs, A. L. Numis and A. M. Andrews , Neurobiology of Disease 16 :572-580 (2004).

• Exploring the relationship between serotonin and brain derived neurotrophic factor: Analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. M. E. Szapacs, T. A. Mathews, L. Tessarollo, W. E. Lyons, L. A. Mamounas and A. M. Andrews , Journal of Neuroscience Methods 140 :81-92 (2004) .

• The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 2'-NH 2 -MPTP . A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell and A. M. Andrews , Molecular Pharmacology, 66 :718-727 (2004).

• Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine . B. A. Luellen, D. B. Miller, A. C. Chisnell, D. L. Murphy, J. P. O'Callaghan and A. M. Andrews , Journal of Pharmacology and Experimental Therapeutics 307: 923-931 (2003).

• 2'-NH 2 -MPTP (1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine) depletes serotonin and norepinephrine in rats: A comparison with 2'-CH 3 -MPTP (1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine). E. L. Unger, P. Mazzola-Pomietto, D. L. Murphy and A. M. Andrews , Journal of Pharmacology and Experimental Therapeutics 303 :527-533 (2002).

• GAP-43 is critical for normal development of the serotonergic innervation in forebrain. S. L. Donovan, L. A. Mamounas, A. M. Andrews , M. E. Blue and J. S. McCasland, Journal of Neuroscience 22 :3543-3552 (2002).

• Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. I. Sora, F. S. Hall, A. M. Andrews , M. Itokawa, X. F. Li, H. B. Wei, C. Wichems, K. P. Lesch, D. L. Murphy and G. R. Uhl , Proceedings of the National Academy of Science USA 98 :5300-5305 (2001).

• Genetic perspectives on the serotonin transporter. D. L. Murphy, Q. Li, S. Engel, C. Wichems, A. M. Andrews , K. P. Lesch and G. Uhl, Brain Research Bulletin 56 :487-494 (2001).

• Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). S. Jayanthi, B. Ladenheim, A. M. Andrews and J. L. Cadet, Neuroscience 91 :1379-1387 (1999).

• Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4- methylenedioxy-methamphetamine (""Ecstasy"") in serotonin transporter-deficient mice. D. Bengel, D. L. Murphy, A. M. Andrews , C. H. Wichems, D. Feltner, A. Heils, R. Mossner, H. Westphal and K. P. Lesch, Molecular Pharmacology 53 :649-655 (1998).

• Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species. L. I. Tsao, B. Ladenheim, A. M. Andrews , C. C. Chiueh, J. L. Cadet and T. P. Su, Journal of Pharmacology and Experimental Therapeutics 287 :322-331 (1998).

• Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. D. L. Murphy, A. M. Andrews , C. H. Wichems, Q. Li, M. Tohda and B. Greenberg, Journal of Clinical Psychiatry 59 :4-12 (1998).

• Gene structure and 5'-flanking regulatory region of the murine serotonin transporter. D. Bengel, A. Heils, S. Petri, M. Seemann, K. Glatz, A. M. Andrews , D. L. Murphy and K. P. Lesch, Brain Research Molecular Brain Research 44 :286-292 (1997).

• Cellular localization and expression of the serotonin transporter in mouse brain. D. Bengel, O. Jφhren, A. M. Andrews , A. Heils, R. Mφίner, G. L. Sanvitto, J. M. Saavedra, K.-P. Lesch and D. L. Murphy, Brain Research 778 :338-345 (1997).

• Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH 2 -MPTP on serotonergic and noradrenergic nerve terminals. A. M. Andrews , B. Ladenheim, C. J. Epstein, J. L. Cadet and D. L. Murphy, Molecular Pharmacology 50 :1511-1519 (1996).

• Differential reinforcing effects of cocaine and GBR-12909: Biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. S. R. Tella, B. Ladenheim, A. M. Andrews , S. R. Goldberg and J. L. Cadet, Journal of Neuroscience 16 :7416-7427 (1996).

• 2'-NH 2 -MPTP in Swiss Webster mice: Evidence for long term (six month) depletions in cortical and hippocampal 5-HT and NE, differential protection by selective uptake inhibitors or clorgyline, and functional changes in central 5-HT neurotransmission. A. M. Andrews and D. L. Murphy, Journal of Pharmacology and Experimental Therapeutics 267 :1432-1439 (1993).

• Fluoxetine and desipramine selectively attenuate 2'-NH 2 -MPTP-induced depletions in serotonin and norepinephrine. A. M. Andrews and D. L. Murphy, European Journal of Pharmacology 250 :215-221 (1993).

• Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH 2 -MPTP): A comparative study with 2'-CH 3 -MPTP and MPTP. A. M. Andrews and D. L. Murphy, Journal of Neurochemistry 60 :1167-1170 (1993).